The truth behind the new obesity miracle-drug and what it could cost large employers
Thursday June 17,
11am PT / 2pm ET
National Pharmacy Clinical Lead, Willis Towers Watson
Sami Inkinen, MSc, MBA
CEO and Co-Founder,
Hassan Azar,JD, MBA, MPH, MHA, MA
VP Global Benefits,
Jones Lang LaSalle
Obesity rates continue to soar, but earlier this month we were met with intriguing news. On June 4th, the FDA approved the weight-loss drug, Wegovy, in which the outcomes which were described as “breakthrough” and “game-changing” Patients on average lost 33.7 pounds after 68 weeks, more than 1.5x higher than the next best obesity drug. Experts predict the record-breaking efficacy rates could unleash the obesity drug market, which has historically lingered at a low <1% penetration rate.
Despite what looks like a promising turn of events at the surface, there is growing concern that we’re at a tipping point for a healthcare cost crisis. With an estimated list price per patient of $13,000, Wegovy (semaglutide) could take a huge hit on employers and payers who are already struggling to control growing medication and healthcare costs.
Join us for a discussion on the topic with commercial and clinical leadership from Willis Towers Watson, JLL, and Virta Health to discuss:
Forecasted impact of Wegovy and obesity drugs for health plans and employers
Cost-effective alternatives for weight loss therapy and diabetes
Real world evidence and case studies of drug elimination success